In addition, CCL5 has been considered as a pro-malignancy indicator in various types of cancer, suggesting that CCL5/CCR5 axis inhibitors (such as UK-427857, Pfizer) are of great potential clinical value, and are therefore have been investigated in many preclinical studies and clinical trials 19. This evidence concerns the gene CCL5 and cancer.